Compare Stocks: HALO, NTRA, BIIB, and ALNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$219.20 +1.4%	$280.12	$197.81 ▼ $495.55	$28.92B	0.3	2.31 million shs	1.74 million shs
BIIB Biogen	$207.94 +0.8%	$202.33	$127.00 ▼ $219.72	$30.48B	0.17	1.37 million shs	840,506 shs
HALO Halozyme Therapeutics	$103.12 +20.2%	$76.48	$61.22 ▼ $103.30	$10.17B	0.85	1.69 million shs	7.69 million shs
NTRA Natera	$322.10 +21.4%	$254.03	$149.38 ▼ $323.01	$38.01B	1.51	1.07 million shs	3.39 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.43%	+6.66%	-32.24%	-25.71%	-48.80%
BIIB Biogen	+0.80%	+2.46%	+3.78%	+7.49%	+60.77%
HALO Halozyme Therapeutics	+20.24%	+24.93%	+28.31%	+60.82%	+65.46%
NTRA Natera	+21.37%	+20.29%	+17.39%	+65.83%	+133.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$219.20 +1.4%	$280.12	$197.81 ▼ $495.55	$28.92B	0.3	2.31 million shs	1.74 million shs
BIIB Biogen	$207.94 +0.8%	$202.33	$127.00 ▼ $219.72	$30.48B	0.17	1.37 million shs	840,506 shs
HALO Halozyme Therapeutics	$103.12 +20.2%	$76.48	$61.22 ▼ $103.30	$10.17B	0.85	1.69 million shs	7.69 million shs
NTRA Natera	$322.10 +21.4%	$254.03	$149.38 ▼ $323.01	$38.01B	1.51	1.07 million shs	3.39 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.43%	+6.66%	-32.24%	-25.71%	-48.80%
BIIB Biogen	+0.80%	+2.46%	+3.78%	+7.49%	+60.77%
HALO Halozyme Therapeutics	+20.24%	+24.93%	+28.31%	+60.82%	+65.46%
NTRA Natera	+21.37%	+20.29%	+17.39%	+65.83%	+133.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$396.72	80.98% Upside
BIIB Biogen	2.56	Moderate Buy	$224.61	8.02% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-11.56% Downside
NTRA Natera	2.77	Moderate Buy	$299.65	-6.97% Downside

Current Analyst Ratings Breakdown

Latest HALO, NTRA, BIIB, and ALNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	NTRA Natera	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$325.00 ➝ $340.00
8/7/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $350.00
8/7/2026	NTRA Natera	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$348.00
8/7/2026	NTRA Natera	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$375.00
8/7/2026	HALO Halozyme Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	NTRA Natera	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$220.00 ➝ $284.00
8/7/2026	NTRA Natera	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$300.00 ➝ $315.00
8/7/2026	NTRA Natera	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $320.00
8/7/2026	NTRA Natera	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$330.00
8/7/2026	NTRA Natera	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$340.00
8/7/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $105.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	6.11	$2.84 per share	77.29	$10.12 per share	21.66
BIIB Biogen	$10.03B	3.06	$22.83 per share	9.11	$127.56 per share	1.63
HALO Halozyme Therapeutics	$1.51B	8.11	$5.74 per share	17.98	$0.42 per share	245.52
NTRA Natera	$2.31B	20.00	N/A	N/A	$12.38 per share	26.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	40.74	22.72	N/A	15.26%	84.93%	14.30%	N/A
BIIB Biogen	$1.29B	$5.65	36.80	12.69	6.37	8.32%	11.18%	6.88%	N/A
HALO Halozyme Therapeutics	$316.89M	$3.35	30.78	11.23	0.36	24.86%	232.11%	24.16%	N/A
NTRA Natera	-$208.16M	-$1.63	N/A	N/A	N/A	-7.11%	-11.82%	-8.19%	N/A

Latest HALO, NTRA, BIIB, and ALNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion
5/11/2026	Q1 2026	HALO Halozyme Therapeutics	$1.54	$1.60	+$0.06	$1.22	$358.60 million	$376.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	3.06
BIIB Biogen	0.39	1.87	1.26
HALO Halozyme Therapeutics	8.81	2.76	2.33
NTRA Natera	N/A	2.96	2.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
HALO Halozyme Therapeutics	97.79%
NTRA Natera	99.90%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
HALO Halozyme Therapeutics	2.50%
NTRA Natera	5.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
HALO Halozyme Therapeutics	390	118.61 million	115.65 million	Optionable
NTRA Natera	6,140	143.21 million	135.98 million	Optionable

HALO, NTRA, BIIB, and ALNY Headlines

Recent News About These Companies

These two biotech stocks hit fresh 52-week highs today – NTRA clocks best day in nearly 20 months

August 8 at 6:59 AM | msn.com

Teamwork Financial Advisors LLC Makes New Investment in Natera, Inc. $NTRA

August 8 at 5:43 AM | marketbeat.com

Natera, Inc. $NTRA Shares Acquired by Assenagon Asset Management S.A.

August 8 at 3:15 AM | marketbeat.com

Natera (NASDAQ:NTRA) Posts Earnings Results, Beats Estimates By $0.02 EPS

August 7 at 12:25 AM | marketbeat.com

Natera, Inc. (NTRA) Q2 2026 Earnings

August 7 at 12:37 PM | 247wallst.com

Natera: Q2 Earnings Snapshot

August 7 at 12:37 PM | chron.com

Natera (NASDAQ:NTRA) reports strong Q2 CY2026, stock jumps 16.3%

August 7 at 12:37 PM | msn.com

IBD 50 stock Natera zips into profit-taking zone on its blowout quarter

August 7 at 12:37 PM | msn.com

JPMorgan Chase & Co. Raises Natera (NASDAQ:NTRA) Price Target to $360.00

August 7 at 12:17 PM | marketbeat.com

Top Biotech Stocks Worth Watching - August 7th

August 7 at 12:03 PM | marketbeat.com

Natera (NASDAQ:NTRA) Hits New 1-Year High on Better-Than-Expected Earnings

August 7 at 9:39 AM | marketbeat.com

Natera Q2 Earnings Call Highlights

August 7 at 2:03 AM | marketbeat.com

Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates

August 6 at 8:13 PM | zacks.com

Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

August 6 at 8:00 PM | seekingalpha.com

Natera, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6 at 6:09 PM | seekingalpha.com

Natera Reports Second Quarter 2026 Financial Results

August 6 at 4:05 PM | businesswire.com

Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

August 6 at 3:32 PM | uk.finance.yahoo.com

John Fesko Sells 295 Shares of Natera (NASDAQ:NTRA) Stock

August 6 at 6:52 AM | insidertrades.com

Bank of America Corp DE Lowers Stake in Natera, Inc. $NTRA

August 6 at 3:20 AM | marketbeat.com

Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 295 Shares

August 5 at 11:06 PM | marketbeat.com

Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 317 Shares

August 5 at 11:06 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HALO, NTRA, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$219.20 +3.08 (+1.43%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$218.44 -0.76 (-0.35%)

As of 08/7/2026 07:57 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$207.94 +1.66 (+0.80%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$207.60 -0.34 (-0.16%)

As of 08/7/2026 07:34 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Halozyme Therapeutics NASDAQ:HALO

$103.12 +17.36 (+20.24%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$101.25 -1.87 (-1.82%)

As of 08/7/2026 07:56 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Natera NASDAQ:NTRA

$322.10 +56.72 (+21.37%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$320.92 -1.18 (-0.36%)

As of 08/7/2026 07:58 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, NTRA, BIIB, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, NTRA, BIIB, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, NTRA, BIIB, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, NTRA, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Natera NASDAQ:NTRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, NTRA, BIIB, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, NTRA, BIIB, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, NTRA, BIIB, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, NTRA, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Natera NASDAQ:NTRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools